The Efficacy of FOLFIRI Plus Ramucirumab in Recurrent Colorectal Cancer Refractory to Adjuvant Chemotherapy with Oxaliplatin/Fluoropyrimidine-Including Biomarker Analyses.
- DOI
- 10.3390/cancers17010091
- Published
- 2024 Dec 30
- Container
- Cancers
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.3390/cancers17010091,
title = {The Efficacy of FOLFIRI Plus Ramucirumab in Recurrent Colorectal Cancer Refractory to Adjuvant Chemotherapy with Oxaliplatin/Fluoropyrimidine-Including Biomarker Analyses.},
author = {Sugimoto N and Noura S and Kato T and Yoshioka S and Hata T and Naito A and Tei M and Tamagawa H and Komori T and Ide Y and Fukuzaki T and Danno K and Sawada G and Kagawa Y and Shimokawa T and Miyoshi N and Ogino T and Uemura M and Yamamoto H and Murata K and Doki Y and Eguchi H},
year = {2024},
journal = {Cancers},
doi = {10.3390/cancers17010091},
url = {https://doi.org/10.3390/cancers17010091}
}RIS
TY - JOUR TI - The Efficacy of FOLFIRI Plus Ramucirumab in Recurrent Colorectal Cancer Refractory to Adjuvant Chemotherapy with Oxaliplatin/Fluoropyrimidine-Including Biomarker Analyses. AU - Sugimoto N AU - Noura S AU - Kato T AU - Yoshioka S AU - Hata T AU - Naito A AU - Tei M AU - Tamagawa H AU - Komori T AU - Ide Y AU - Fukuzaki T AU - Danno K AU - Sawada G AU - Kagawa Y AU - Shimokawa T AU - Miyoshi N AU - Ogino T AU - Uemura M AU - Yamamoto H AU - Murata K AU - Doki Y AU - Eguchi H PY - 2024 JO - Cancers DO - 10.3390/cancers17010091 UR - https://doi.org/10.3390/cancers17010091 ER -
APA
N, S., S, N., T, K., S, Y., T, H., A, N., M, T., H, T., T, K., Y, I., T, F., K, D., G, S., Y, K., T, S., N, M., T, O., M, U., H, Y., K, M., Y, D., & H, E. (2024). The Efficacy of FOLFIRI Plus Ramucirumab in Recurrent Colorectal Cancer Refractory to Adjuvant Chemotherapy with Oxaliplatin/Fluoropyrimidine-Including Biomarker Analyses.. Cancers. https://doi.org/10.3390/cancers17010091
Source records
- pubmed · retrieved 2026-09-26T20:34:37.935Z